drugset / Trial / NCT04237649
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of the trial was to characterize the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose (RD) for expansion of single agent KAZ954 and KAZ954 in combination with PDR001, NIR178 and NZV930.
Timeline
- Start
- 2020-02-20
- Primary completion
- 2023-09-15
- Completion
- 2023-09-15
Outcome
Outcome not reported
Stopped (Business): “Business reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KAZ954 | Unknown | — | — |
| Subject | NIR178 | Unknown | — | — |
| Subject | NZV930 | Unknown | — | — |
| Subject | Spartalizumab | Monoclonal antibody | — | — |